Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P7 | DOI: 10.1530/endoabs.90.P7

ECE2023 Poster Presentations Adrenal and Cardiovascular Endocrinology (72 abstracts)

Treatment compliance affects the reliability of clinically and biochemically important variables used for the titration of mineralocorticoid treatment in primary adrenal insufficiency

Riccardo Pofi 1 , Ilaria Bonaventura 2 , Joanne Duffy 3 , Zoe Maunsell 4 , Brian Shine 4 , Andrea Isidori 2 & Jeremy Tomlinson 1


1Oxford Centre for Diabetes, Endocrinology and Metabolism and NIHR Oxford Biomedical Research Centre, Department of Endocrinology, Oxford, United Kingdom; 2Sapienza University of Rome, Department of Experimental Medicine, Rome, Italy; 3Heartlands Hospital, Department of Clinical Chemistry and Immunology, Birmingham, Oxford, United Kingdom; 4Oxford University Hospitals NHS Foundation Trust, Department of Clinical Biochemistry, Oxford, United Kingdom


Background: There is currently no agreed consensus for the optimization and titration of mineralocorticoid (MC) therapy in patients with primary adrenal insufficiency (PAI).

Objective: To measure serum (sFC) and urine (uFC) fludrocortisone levels and explore their relationship with biochemically and clinically important variables (including treatment compliance) in order to evaluate their usefulness as markers to guide the MC replacement titration.

Methods: Multi-centre, observational, cross-sectional study on 41 patients (median age 39 years, IQR 27-56) with PAI on MC replacement therapy (median dose 100 mg/d, range 50-400). sFC and uFC levels (measured by LC-MS/MS), plasma renin concentration (PRC), electrolytes (Na+, K+), mean arterial blood pressure (MAP), total daily Glucocorticoid (dGC, hydrocortisone equivalents) and MC (dMC) dose, anthropometrics and assessment of GC and MC treatment compliance were incorporated into statistical models.

Results: We observed a close relationship between sFC and uFC (r=0.434, P=0.005) as well as between sFC and the time from the last FC dose (r=-0.355, P=0.023). Total daily MC dose was related to dGC dose (r=0.556, P<0.001), K+ (r= -0.388, P=0.013) as well as sFC (r=0.356, P=0.022) and uFC (r=0.531, P<0.001) levels. PRC was related to Na+ levels (r=0.517, P<0.001) and MAP (r=-0.427, P=0.006), but not to MC dose, sFC or uFC . Multiple linear regression analyses did not support a role for sFC, uFC or PRC measurements and confirmed K+ (B=-44.593, p=0.005) as the most important variable to guide dMC titration. However, when compliance was inserted into the model, it was the only factor affecting dMC.

Conclusions: sFC and uFC levels are not helpful in dMC titration in PAI. Clinicians should continue to rely on clinical and biochemical important variables (electrolytes, blood pressures and symptoms) to guide their decisions on MC dose adjustment, being aware that patient’s compliance to treatment is a major contributor for the reliability of such clinical markers.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.